prejudice for related proteins. To support the ligand-based view of protein organization, Lin et al. 2 created ligand-derived dendrograms.
The authors demonstrate that this approach allows for a similarity representation more in line with what a medicinal chemist or pharmacologist would judge as 'similar' proteins. When dendrograms are constructed on the basis of ligand similarity, major topological differences from classical evolutionary dendrograms constructed on the basis of sequence similarity are observed (Fig. 1) . For instance, the opioid receptors are observed to be related by ligand binding similarity to many aminergic receptors, thus reflecting well-established medicinal chemistry structure-activity relationship patterns. A major advantage to this approach is that the similarity of proteins that are from completely different families but known to bind similar ligands can be more accurately captured. For example, the NTSR1 neurotensin 1 receptor is demonstrated to share ligand similarity with sortilin. More importantly, the authors show experimentally that a subset of their predictions are valid, as they detected ligands binding to proteins that they are predicted to bind, without prior knowledge. They experimentally confirmed both predictions of novel GPCR ligands based on chemical similarity and predictions of novel ligands for non-GPCRs based on chemical similarity, corroborating the general applicability of the method.
A limitation of the approach pursued by Lin et al. 2 is that it requires prior knowledge of which ligands bind to a protein. Hence, GPCRs (or other proteins) for which no-or a limited number or diversity of-ligands are known cannot be included in this approach directly. Furthermore, the assumption is made that all relevant ligands for each protein are known; identification of new ligands for a certain protein will certainly restructure the similarity relationships. Finally, the method cannot be used to quantitatively estimate the strength of the interaction between a protein and ligand and cannot differentiate directly whether ligand A binds better than ligand B. In these cases, methods relying on sequence similarity (or a combination of sequence and chemical similarity) might still prove instrumental 11 .
The Lin et al. 2 approach should lead to many new and exciting applications based on this framework for clustering the genome around ligand binding similarity relationships. Examples include the improved prediction of drug side effects and the design of drugs that simultaneously hit multiple targets (polypharmacology), perhaps even in a single pathway. Applications in more fundamental research, speculated on by the authors, are equally tantalizing. For example, the different time scales of physiological response to ligand signals (from milliseconds to days) would be expected to exploit different signaling systems containing differing gene families. Epigenetics is the study of information heritable during cell division other than DNA sequence per se. As such, epigenetics is an essential pathway to understanding the mechanism for the development of multicellular organisms with distinct cell types and Andrew P. Feinberg is at the Center for Epigenetics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. e-mail: afeinberg@jhu.edu npg the diseases that involve disruption of those developmental pathways. These include obesity, cardiovascular disease, neurodegenerative disease and cancer. Moreover, tissues do not exist in a state of homogeneity; rather, each tissue exhibits considerable variability within itself, in phenotype and responsiveness. Yet our approach to the study of mammalian epigenetics almost always involves analysis of homogenized tissues, or at least many fractionated cells from a given tissue. And our approach to medical diagnostics and treatment is almost entirely geared toward analysis of mean values and mean phenotypes, such as the 'cancer cell' or 'atherosclerotic lesions' . Gomez et al. 1 
I teach my students not to read News and Views articles, or the abstract of the original paper, until they have looked at the figures; so in that spirit I ask you to examine, at the risk of not finishing this piece, Figure 1c of the article by Gomez et al. 1 This shows a specific activated chromatin mark at a specific gene-that is, a dimethylation mark at lysine 4 on histone H3 (H3K4me2) on MYH11, a gene whose expression is specific for smooth muscle cells (SMCs)-as a small pink dot at the end of the arrows. What is very cool is that we can see that the modification occurs only in SMCs that line the small blood vessels in this atherosclerosis model. Now jump to Figure 4 panels e and f. Using the same methodological trick, the authors show that this same epigenetic mark, which tags SMCs, is part of experimentally induced atherosclerotic lesions, even though conventional staining for SMCs with antibodies against the gene products of MYH11 and ACTA2 could not reveal this because the genes are downregulated. The authors know that they are examining SMCs because they went to the trouble of engineering a lineage-specific transgenic tag, but now that they know that H3K4me2 on MYH11 is specific for SMCs, they no longer have to use such a transgene to examine the SMC-lineage contribution to human pathology. They do just that in Figure  5b , showing again that the epigenetic mark tags SMCs in human atherosclerotic lesions even though conventional gene-product immunostaining is negative. This means that pathologists may have underestimated the role of SMCs in human atherosclerosis; the current study provides support to investigators studying SMC therapeutic targeting for this disease 2 and, more importantly, provides a method for studying the effects of such intervention directly on the targeted tissue itself rather than the more complex end phenotype of heart disease.
So what is the method in the paper? It is a variation of the proximity ligation assay (PLA), which the current authors call, noneuphoniously, ISH-PLA, because it involves in situ hybridization (ISH) added to the PLA. The PLA was first developed by Ulf Landegren to detect protein interactions, and in its original version it used two DNA aptamers selected for their targeting of a given pair of proteins 3 . When the aptamers were close enough because of target-protein interaction, they could ligate to a linker, and then the ligation products could be detected by PCR. In a subsequent version, the signal was enhanced by rolling circle amplification, which allowed in situ analysis; hence its name of proximity ligation in situ assay, or P-LISA. Gomez et al. 1 adapted the latter method by using a biotinylated probe targeting the gene of interest, in this case MYH11, and another probe targeting the chromatin modification, namely H3K4me2 (Fig. 1a) . They conjugated PLA probes to rabbit anti-biotin and mouse H3K4me2 primary antibodies. In theory, then, the method can be applied to any gene-chromatin mark pair. I am excited by the potential application of the method to visualize higher-order chromatin modifications of genomic regions, such as large organized chromatin K-modifications 4 or lamina-associated domains 5 , which are thought to change during development 4, 6 , epithelial-mesenchymal transition 7 and cancer 6 . Such experiments might be combined with optical methods for visualizing the relationship of these modified regions to the nuclear membrane in cell populations. Another promising application of the new method is in examination of the cellular heterogeneity of epigenetic marks (Fig. 1b) . Epigenetic information may be represented not only in the mean, but also in the variability of the mark, allowing for greater plasticity of a tissue's response to the environment. Such epigenetic heterogeneity has been observed indirectly [8] [9] [10] , but using this method, it could be observed directly.
The current study also shows the far-reaching contribution of inventors, who are often underappreciated by the scientific community, except for by other inventors. The current paper is a third-generation invention. The first-generation method in this case was obviously PCR itself. But for the second generation, PLA, the credit goes to Landegren, a softspoken and generous Swedish 'methods guy' at Uppsala University. He also invented padlock probes 11 , which, along with their variants, lie at the heart of methods for capture-based genome sequencing strategies. I'm not sure that the current American funding system would appreciate Professor Landegren, as study sections generally reward biology over technology, but I, for one, am extremely grateful for his contributions. 
